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Abstract
Background: Palliative systemic therapy is currently standard of care for patients 
with extensive metastatic colorectal cancer (mCRC). A biomarker predicting chemo-
therapy benefit which prevents toxicity from ineffective treatment is urgently needed. 
Therefore, a previously developed tissue-derived microRNA profile to predict clini-
cal benefit from chemotherapy was evaluated in tissue biopsies and serum from pa-
tients with mCRC.
Methods: Samples were prospectively collected from patients (N = 132) who 
were treated with capecitabine or 5-FU/LV with oxaliplatin  ±  bevacizumab. 
Response evaluation was performed according to RECIST 1.1 after three or 
four cycles, respectively. Baseline tissue and serum miRNAs expression levels 
of miR-17-5p, miR-20a-5p, miR-30a-5p, miR-92a-3p, miR-92b-3p, and miR-
98-5p were quantified with RT-qPCR and droplet digital PCR, respectively. 
Combined predictive performance of selected variables was tested using logis-
tic regression analysis.
Results: From 132 patients, 81 fresh frozen tissue biopsies from metastases and 93 
serum samples were available. Based on expression levels of miRNAs in tissue, pro-
gressive disease could be predicted with an AUC of 0.85 (95% CI:0.72-0.91) and 
response could be predicted with an AUC of 0.70 (95% CI:0.56-0.80). This did not 
outperform clinical parameters alone (respectively P = .14 and P = .27). Expression 
levels of miR-92a-3p and miR-98-5p in serum significantly improved the predictive 
value of clinical parameters for response to chemotherapy (AUC 0.74, 95% CI:0.64-
0.84, P = .003) in this cohort.
Conclusions: The additive predictive value to clinical parameters of the tissue-de-
rived six miRNA profile for clinical benefit could not be validated in patients with 
mCRC treated with first-line systemic therapy. Although miR-92a-3p and miR-98-5p 
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1 |  INTRODUCTION
MicroRNAs (miRNAs) are small noncoding RNAs that have 
an impact on many important biological processes by regula-
tion of protein expression levels. In addition, miRNAs have 
favorable biomarker characteristics as they are easy to detect 
and resistant to degradation. Prior studies showed that tissue 
miRNAs are differentially expressed between normal and 
tumor tissue and between tumor subtypes. Furthermore, it 
has been observed that miRNAs from tumor cells are secreted 
into the circulation and can be detected in blood plasma and 
serum.1,2
Since it is possible to reliably detect miRNAs in human 
blood specimens, interest has shifted toward using miRNAs 
as a liquid biomarker. Tumor specific miRNAs may be re-
leased into the blood circulation through active secretion in 
exosomes or through passive secretion by cell death.3 Patients 
with high tumor load are expected to have high levels of tumor 
specific circulating miRNAs (ci-miRNAs). Previous studies 
have shown significant correlations between ci-miRNAs and 
tumor stage and between paired tissue and serum miRNA ex-
pression levels.4,5 These ci-miRNAs could function as a min-
imally invasive predictive biomarker for disease monitoring 
upon treatment.
Among cancer types, colorectal cancer (CRC) ranks 
in the top 3 for incidence and mortality worldwide.6,7 
Approximately half of all patients diagnosed with CRC 
will have metastasis at diagnosis or develop them during 
the course of their disease.8 For patients with extensive 
metastatic disease, no treatment with curative intent is 
available. Standard of care for these patients is palliative 
systemic treatment that usually consists of 5-FU-based 
combination chemotherapy with oxaliplatin and/or irino-
tecan, anti-VEGF targeted therapy, and anti-EGFR anti-
bodies. Overall survival with these modern regimens is an 
estimated 30 months.9,10 Currently, only for the use of an-
ti-EGFR therapy a biomarker of response is available and 
it is recommended to exclude RAS and BRAF mutant tu-
mors and right-sided primary tumors from anti-EGFR ther-
apy.11,12 Since approximately 10%–20% of the patients do 
not benefit from first-line chemotherapy and will have pro-
gressive disease at first evaluation, there is a strong clinical 
need for a predictive biomarker.9,10,13,14
Previously, a model to predict response to palliative sys-
temic treatment in patients with mCRC based on primary 
tumor expression of miRNAs and clinicopathological fac-
tors was developed. Six miRNAs (miR-17-5p, miR-20a-5p, 
miR-30a-5p, miR-92a-3p, miR-92b-3p and miR-98-5p) 
combined with four clinical parameters (the use of adjuvant 
chemotherapy after resection of the primary tumor, age, 
tumor differentiation, and type of systemic treatment, ie, 
oxaliplatin or irinotecan based) were predictive for clini-
cal benefit with an AUC of 0.78.15 Furthermore, expression 
profiles of primary CRC tissues and metastatic lesions are 
highly comparable.16
Three of these miRNAs (miR-17-5p, miR-20a-5p, and 
miR-92a-3p) belong to the miR-17-92 cluster, also known 
as oncomir-1. miRNAs from this cluster are involved in 
tumor angiogenesis, treatment resistance, and CRC progres-
sion.17-20 The other miRNAs, miR-30a-5p, miR-92b-3p, and 
miR-98-5p are involved in proliferation of CRC cells.21-23 In 
addition, high expression of miR-92b-3p has previously been 
related to a prolonged progression-free survival in patients 
with mCRC treated with combined FOLFOX and bevaci-
zumab.24 The current study aimed to prospectively validate 
the predictive value of clinical benefit from systemic treat-
ment of the previously identified miRNA signature in a 
cohort of patients with extensive mCRC, starting first-line 
palliative systemic therapy.
2 |  MATERIAL AND METHODS
2.1 | Tissue and serum samples
In total 132 consecutive patients enrolled in a clinical trial 
(the ORCHESTRA trial) between May 2013 and February 
2017 were included for miRNA analysis. This trial is a rand-
omized multicenter clinical trial for patients with multiorgan 
colorectal cancer metastases comparing the combination of 
chemotherapy and maximal tumor debulking vs chemother-
apy alone (clinicaltrials.gov Identifier: NCT01792934).25 
Of all patients, tissue samples and serum biopsies were 
prospectively collected as part of the translational study 
program.
Written informed consent was obtained from all patients 
included in this trial.26-28 At baseline, one to four fresh fro-
zen 14-18 G needle biopsies were obtained (ultrasound or CT 
guided) from a metastatic lesion or from the primary tumor 
(endoscopically). The biopsy specimen was transferred to 
serum levels improved the predictive value of clinical parameters, it remained insuf-
ficient for clinical decision-making.
K E Y W O R D S
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a storage tin and snap frozen in liquid nitrogen and subse-
quently stored at −80°C.
Serum samples were collected in a BD vacutainer® tube, 
incubated upright for 1 hour and centrifuged at 1500 × g for 
10 minutes at room temperature. Samples were aliquoted and 
stored at −80°C until RNA isolation. Specimens were col-
lected prior to the start of systemic therapy.
Clinical parameters were documented and included age, 
gender, primary tumor sidedness (left or right), number of 
organs involved in metastatic disease, primary tumor in situ 
(yes or no), number of metastatic lesions (<5, 5-10, >10 
or diffuse disease), differentiation (well/moderately, poor), 
prior (neo-) adjuvant chemotherapy (yes or no), CEA (ele-
vated > 5 ng/µL, normal), LDH (elevated > 250 ng/µL, or 
normal).
All patients were treated with 5-FU/LV or capecitabine 
and oxaliplatin (46-hour continuous infusion of 5-FU/LV and 
oxaliplatin in a biweekly schedule (FOLFOX) or oxaliplatin 
IV followed by 14 days of oral capecitabine in a 3-week cycle 
(CAPOX))  ±  bevacizumab at physician discretion. After 
three cycles of CAPOX(B) or four cycles of FOLFOX(B) a 
CT scan of thorax and abdomen was performed. Follow-up 
scans were performed at least every 3 months and evaluated 
according to RECIST v 1.1.29
2.2 | RNA extraction
2.2.1 | Tissue
Dissection of fresh frozen biopsies was performed at ap-
proximately −25°C in a cryotome. Biopsies were enriched 
for tumor cells by macro dissection. Twenty micrometer 
sections were cut and snap frozen in liquid nitrogen and 
stored at −80°C until RNA extraction. Multiple 5  µmol/L 
sections were stained with hematoxylin and eosin (H&E) 
to confirm the presence of tumor cells across the biopsy. As 
stromal infiltration is a characteristic for worse prognosis, 
stromal percentage was included into tumor purity estima-
tion.30 The percentage of tumor field was defined as the sum 
of the percentage of tumor cells and the percentage of stro-
mal cells. Samples were included if the percentage of tumor 
field was ≥ 30% as scored by a pathologist. RNA was iso-
lated using the AllPrep® DNA/RNA/miRNA Universal Kit 
(Qiagen) according to the manufacturers protocol, eluted in 
30-µL-nuclease free water and quantified using a Nanodrop 
2000 (Thermo Scientific).
2.2.2 | Serum
Serum RNA was extracted using the miRNeasy Serum/
Plasma advanced Kit (Qiagen, former Exiqon).31 During 
RNA extraction a DNase step was included using the RNase-
Free DNase Set (Qiagen) according to the manufacturers 
protocol.
2.3 | Hemolytic index
The hemolytic index (HI) of serum samples was measured 
using the automated Roche Modular Cobas 8000 platform 
according to the instructions of the manufacturer. Serum 
samples with a HI ≥ 10 were excluded for further analysis, 
since blood cells contain a lot of miRNAs and significant cor-
relations between the HI and expression of certain ci-miR-
NAs was demonstrated before.31,32
2.4 | miRNA quantification
2.4.1 | Tissue
miRNAs miR-16-5p, miR-17-5p, miR-20a-5p, miR-30a-
5p, miR-92a-3p, miR-92b-3p, and miR-98-5p were 
quantified with reverse transcription quantitative PCR 
(RT-qPCR) and analyzed as previously described.15 The 
chemicals from Exiqon were replaced with the chemicals 
from Qiagen as Exiqon merged with Qiagen, using the 
miRCURY LNA RT kit for cDNA synthesis and the miR-
CURY LNA miRNA PCR assays together with miRCURY 
LNA SYBR® Green for miRNA quantification (Qiagen). 
Cq values were normalized with miR-16-5p as reported 
previously.4,15,33,34
2.4.2 | Serum
cDNA synthesis was performed with the miRCURY LNA RT 
kit (Qiagen) using 3-µL-extracted RNA. Serum RNA qual-
ity was assessed by measuring synthetic miRNA spike-in of 
cel-miR-39-3p with RT-qPCR as described above using cel-
miR-39-3p miRCURY LNA miRNA PCR assay (Qiagen). 
Samples were selected for droplet digital PCR (ddPCR) anal-
ysis if the raw Cq value was ≤ 30.31 cDNA was diluted 1:40 
for ddPCR. Each ddPCR reaction consisted of 9.9-µL-diluted 
cDNA, 11 µL of QX200 EvaGreen ddPCR Supermix (Bio-
Rad, Veenendaal, The Netherlands), and 1.1-µL-optimal 
concentration miRCURY LNA miRNA PCR assay. The op-
timal PCR assay volume was experimentally assessed for 
each assay using 1.0-µL, 0.5-µL, and if necessary 0.25-µL 
assay diluted in nuclease free H2O (Figure  S1A). A gradi-
ent (52°C-62°C) ddPCR was performed for each assay to de-
fine the optimal annealing temperature (Figure S1B). Similar 
PCR assays were used as described in the section tissue 
miRNA quantification.
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Twenty-microliter ddPCR reaction mix and subsequently 
70 µL QX200TM droplet generation oil for EvaGreen (Bio-
Rad) was loaded on a DG8TM Cartridge for QX200TM/
QX100TM droplet generator. Droplets were generated in a 
QX200TM droplet generator and a total of 40 µL was loaded 
in a ddPCRTM 96-Well-PCR plate (Bio-Rad). Each plate in-
cluded a nontemplate control (NTC) and positive control for 
each PCR assay with H2O and RNA from cancer cell lines 
as described previously.15 The PCR reaction was performed 
in a Thermal cycler (Bio-Rad) with a three-step protocol; (a) 
Enzyme activation: 5 minutes at 95°C, (b) PCR: 30 seconds 
at 95°C and 1 minute at primer specific annealing tempera-
ture repeated 40 times, (c) droplet stabilization: 5  minutes 
4°C, 5  minutes 95°C, and at 4°C until droplet reading. 
Droplets were quantified in a Droplet Reader QX200TM (Bio-
Rad) and the number of formed droplets was obtained using 
QuantaSoft software (Bio-Rad). If less than 10 000 droplets 
were formed, the PCR reaction for that particular sample was 
repeated. Threshold estimation to define positive and nega-
tive droplets together with absolute miRNA quantification 
was performed using the R-package “ddpcRquant” designed 
by Trypsteen and colleagues.35 The standard “ddpcRquant” 
package was designed for single plate analysis. Because the 
number of samples in this study exceeded the number wells 
of a single 96-well plate, the script was adapted to analyze 
multiple plates for the same assay. The final miRNA con-
centration in copies per µL cDNA was log2 transformed and 
normalized for technical variation with log2 transformed cel-
miR-39-3p levels as described previously.31,33
2.5 | Statistical analysis
Predicting response after three to four cycles of chemother-
apy was tested for two scenarios (a) clinical benefit (CB) de-
fined as complete response (CR), partial response (PR), and 
stable disease (SD) together vs progressive disease (PD) and 
(b) CR or PR vs SD or PD. The models for response predic-
tion as designed previously 15 were tested with the combined 
miRNA expression and clinicopathological data collected 
from the current cohort (FF cohort). New prediction models 
were formed for different clinical endpoints with multivari-
ate logistic regression analysis using Akaike's information 
criterion (AIC)-based backward selection for selection of the 
best model. For the new prediction models the clinical pa-
rameter “type of systemic treatment” was excluded because 
all patients in the current FF cohort received the same sys-
temic treatment. Performance of the models was evaluated by 
comparing AUCs of paired ROC curves (clinicopathological 
factors vs added value of the miRNA expression to these fac-
tors) as described before.15
As the prediction coefficients of the miRNAs from the 
models in the previous study (original FFPE cohort) are 
based on its miRNA expression levels, the miRNA expres-
sion levels in the FF cohort were compared with the expres-
sion levels in the original FFPE cohort.15 Because the FF 
cohort consisted only of patients with stage IV disease, and 
the original FFPE cohort consisted of patients with stage I 
to IV disease, the miRNA expression data from the original 
FFPE cohort were grouped in stage I-III and IV disease. 
Two comparisons were performed: (a) miRNA expression 
levels between stage I-III and IV in the original FFPE co-
hort and (b) miRNA expression between stage IV in the 
original FFPE cohort and stage IV in the FF cohort. The 
Welch's two sample t test or two-sample t test were used for 
these comparisons.
Baseline characteristics from the patients in the FF cohort 
were compared to the baseline characteristics from the pa-
tients in the original FFPE cohort,15 as well as for the patients 
from the serum and tissue cohorts in the FF cohort. Fisher's 
exact two-sided test, Pearson two-sided Chi-Square test or 
an unpaired t test were used to test significance in baseline 
characteristics between the different cohorts. P values < .05 
were considered statistically significant. Log2 normal-
ized expression data were used to correlate serum vs tissue 
miRNA expression data. Unsupervised cluster analysis was 
performed with log2 transformed normalized serum and tis-
sue miRNA expression levels using ward.D2 clustering and 
Manhattan distance. Statistical analysis was performed using 
the R-package “CompareGroups” using R studio (version 
1.1.423) with R software (version 3.5.0) downloaded from 
Bioconductor.36-38
3 |  RESULTS
From May 2013 to March 2017, 132 patients with mCRC 
were included in the trial and available for analysis. From 
29 patients no baseline tissue biopsy was available and from 
12 patients, no baseline serum sample was available, leaving 
a total of 103 tissue samples (fresh frozen cohort) and 120 
serum biopsies. Both serum and tumor biopsies were avail-
able in 95 patients.
From the available tissue samples, 22 were excluded 
due to a tumor field percentage  <  30%, leaving a tissue 
cohort of 81 samples for further analyses. From 120 avail-
able serum samples, 24 were excluded due to a hemolytic 
index  >  10, two were excluded because the hemolytic 
index was not assessable and one was excluded because 
of poor RNA quality (Figure 1), leaving a serum cohort of 
93 samples. From 58 patients, miRNA expression could be 
quantified with good quality from both serum and tumor 
sample.
No significant differences were observed between the 
clinicopathological characteristics from the tissue cohort 
(N = 81) and the serum cohort (N = 93) (Table S1). Tumor 
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field percentage ranged from 30% to 100% with a median 
of 100% and a mean of 86% (Figure 2A). Of the included 
samples in the tissue cohort 53 (65%) were from liver me-
tastases. Biopsies were collected from eight different organs 
(Figure  2B). Unsupervised cluster analysis of log2 trans-
formed, miR-16-5p normalized, tissue miRNA expression 
data revealed two specific clusters. These clusters were not 
related to tumor field percentage (categorized in 30-50%, 
51%-80% and 81%-100%), location of the primary tumor 
(left- vs right-sided colon vs rectum), tumor-site biopsy (liver 
vs other) (Figure 2C).
In the serum cohort, raw Cq values of cel-miR-39-3p 
quantified with RT-qPCR ranged from 26 to 30 with a 
median of 28,38 (Figure 3A). Unsupervised cluster anal-
ysis of log2, cel-miR-39-3p normalized, serum miRNA 
expression data showed that cluster membership was not 
correlated to the location of the primary tumor, hemo-
lytic index, or primary tumor location. In serum, high 
miRNA expression was observed for miR-92a-3p, miR-
20a-5p, and miR-17-5p, whereas low expression was 
observed for miR-30a-5p, miR-92b-3p, and miR-98-5p 
(Figure 3B).
F I G U R E  1  Sample flow chart of the 
included tissue and serum biopsies
F I G U R E  2  Tumor percentage, 
sample characteristics, and tissue miRNA 
expression. A, Boxplot of percentage of 
tumor field (tumor stroma plus tumor cells) 
per biopsy. Tumor field percentage was 
30%-100% with a median of 100% and an 
average of 86%. B, numbers and location of 
the different biopsies included in the tissue 
cohort. C, Unsupervised cluster analysis 
of log2, normalized to miR-16-5p, tissue 
miRNA expression levels. prim. tumor loc.: 
primary tumor location; norm.: normalized 
to miR-16-5p
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3.1 | Prediction of treatment benefit
3.1.1 | Tissue
In the tissue cohort five patients (6.17%) showed PD, 39 
(48.1%) had SD, and 37 (45.7%) had PR after three or four cy-
cles of chemotherapy (Table 1). The miRNA expression lev-
els from the fresh frozen cohort combined with the age, tumor 
differentiation, use of adjuvant chemotherapy after primary re-
section, and type of palliative systemic therapy revealed low 
predictive value for treatment response in contrast to the previ-
ously developed model. Here, using the previously developed 
predictive model for CR and PR vs PD that included miR-92a-
3p, miR-92b-3p, and the three clinicopathological covariates 
as variables, resulted in an AUC of 0.60, 95% CI, 0.35-0.85. 
Using the predictive model for CR and PR vs SD that included 
miR-17-5p, miR-92a-3p, miR-92b-3p, miR-98-5p, and differ-
entiation grade of the primary tumor as variables, resulted in an 
AUC of 0.51, 95% CI, 0.37-0.64.15
When performing a new backward selection starting with 
all nine variables and using AIC for model selection, the best 
predictive model contained expression levels of miR-17-5p, 
miR-92b-3p, and miR-98-5p only. Prediction of clinical benefit 
vs progressive disease at first evaluation by measured expres-
sion levels of these three miRNAs revealed a model with an 
AUC of 0.85 (95% CI: 0.72-0.91) (Figure 4A). The AUC of 
this model is higher compared to the AUC of the model with 
the parameters age, tumor differentiation, and prior use of ad-
juvant chemotherapy alone (AUC: 0.74, 95% CI, 0.56-0.92), 
but did not reach statistical significance (P = .14). The calcu-
lated predicted probabilities from the model are visualized in 
Figure 4B. For PD the predicted probabilities ranged between 
0.04 and 0.53 with a median of 0.16 and for CR, PR and SD the 
predicted probabilities ranged between < 0.01 and 0.30 with 
a median of 0.16 (Figure 4B). Addition of miRNA expression 
levels to the clinicopathological covariates did not significantly 
improve the performance of the model to discriminate between 
patients with objective response (CR and PR) (n = 37) vs SD 
and PD (n = 44), (AUC: 0.67, 95% CI:0.55-0.79 vs AUC: 0.70, 
95% CI:0.56-0.80 with miRNAs, P = .27) (Figure 4C), with a 
wide range of predicted probabilities (Figure 4D). For objective 
response the predicted probabilities ranged between 0.17 and 
0.81 with a median of 0.47 and for SD and PD this ranged be-
tween 0.25 and 0.91 with a median of 0.58 (Figure 4D).
3.1.2 | Serum
In the serum cohort, logistic regression analysis could not 
be performed because only three (3.2%) patients showed 
F I G U R E  3  Serum RNA quality, 
sample characteristics, and serum miRNA 
expression. A, RNA quality control of 
RNA extracted from serum samples using 
cel-miR-39-3p expression levels quantified 
with RT-qPCR. Raw Cq values of cel-
miR-39-3p are presented in a boxplot. 
Raw Cq values were 26-30 with a median 
of 28 B, Unsupervised cluster analysis of 
log2, normalized to cel-miR-39-3p, serum 
miRNA expression levels. HI: Hemolytic 
index; prim. tumor loc.: primary tumor 
location; norm.: normalized to cel-miR-39-
3p
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T A B L E  1  Comparison of the patient cohort used to compute the initial response prediction models (original FFPE cohort) vs the cohort used 
for this study (FF cohort)
Prior cohort FFPE FF cohort P value
N = 81 N = 81
Gender .870
Female 30 (37.0%) 28 (34.6%)
Male 51 (63.0%) 53 (65.4%)
Age at diagnosis (median - range) 61 (37 - 81) 64 (28 - 81) .129
Primary tumor location:
Rectal 20 (24.7%) 34 (42.0%) .064
Left sided 30 (37.0%) 22 (27.2%)
Right sided 31 (38.3%) 25 (30.9%)
Stage <.001
I 1 (1.20%) 0 (0.00%)
II 13 (16.0%) 0 (0.00%)
III 12 (14.8%) 0 (0.00%)
IV 54 (66.7%) 81 (100%)
Unknown 1 (1.20%) 0 (0.00%)
Differentiation .943
Well/moderately differentiated 54 (66.7%) 54 (66.7%)
Poorly differentiated 15 (18.5%) 16 (19.8%)
Other 0 (0.00%) 1 (1.23%)
Unknown 12 (14.8%) 10 (12.3%)
Prior adjuvant therapy .072
Yes 7 (8.60%) 16 (19.8%)
No 74 (91.4%) 65 (80.2%)
Liver metastases only <.001
No 57 (70.4%) 81 (100%)
Yes 24 (29.6%) 0 (0.00%)
LDH (cut-off 250 ng/µL) <.001
Elevated 55 (67.9%) 18 (22.2%)
Normal 23 (28.4%) 56 (69.1%)
Unknown 3 (3.70%) 7 (8.64%)
CEA (cut-off 5 ng/µL)
Elevated 61 (75.3%) 55 (67.9%) .643
Normal 17 (21.0%) 22 (27.2%)
Unknown 3 (3.70%) 4 (4.94%)
First-line treatment scheme <.001
5-FU monotherapy 14 (17.3%) 0 (0.00%)
Oxaliplatin-based regimen 57 (70.4%) 81 (100%)
Irinotecan-based regimen 10 (12.3%) 0 (0.00%)
Use of first-line Bevacizumab <.001
No 51 (63.0%) 21 (25.9%)
Yes 30 (37.0%) 60 (74.1%)
Best response to first-line treatmenta 
Complete response (CR) 2 (2.5%) 0 (0.00%) .025
(Continues)
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PD after three to four cycles of chemotherapy. When sepa-
rating the study cohort in objective response vs SD and 
PD after three to four cycles of chemotherapy, a model 
with miR-92a-3p and miR-98-5p expression combined 
with previous adjuvant chemotherapy and tumor differen-
tiation showed a significant better performance compared 
to the model with clinicopathological factors alone (AUC 
0.74, 95%CI 0.64-0.84 vs AUC 0.67, 95%CI 0.56-0.78; 
P = .003) (Figure 5A). The calculated predicted probabili-
ties are visualized in Figure 5B which ranged between 0.08 
and 0.88 with a median of 0.42 for CR and PR (n = 46) 
vs 0.15 and 0.90 with a median of 0.59 for SD and PD 
(n = 47) (Figure 5B). From 58 patients, tissue and serum 
expression data were available. There was no correlation 
between tissue and serum expression of these six miRNAs 
(R = −0.11; P = .42) (Figure 5C).
3.2 | Comparison with original formalin-
fixed paraffin-embedded (FFPE) cohort
Baseline characteristics of current FF cohort and the original 
FFPE cohort are shown in Table 1. There are significant dif-
ferences in tumor stage (P < .001), with the current FF co-
hort including only patients with extrahepatic disease (stage 
IV) at diagnosis vs all stages at diagnosis in our original co-
hort. In the current FF cohort, a lower percentage of elevated 
LDH (P <  .001) was observed and baseline tissue biopsies 
were from different locations (metastasis vs primary tumor) 
(P  <  .001). Systemic treatment schedules differed signifi-
cantly for both chemotherapy (P < .001) and use of bevaci-
zumab (P < .001). Also, response to therapy was significant 
different (P = .03) Table 1.
No differences were observed between miRNA expres-
sion in stage I-III and IV in the original FFPE cohort. All six 
miRNAs were significantly higher expressed in the current 
FF cohort compared to the original FFPE cohort ((P = .03; 
miR-92a-3p) and P  <  .01; miR-17-5p, miR-20a-5p, miR-
30a-5p, miR-92b-3p, miR-98-5p) (Figure 6).
4 |  DISCUSSION
In this prospective study we aimed to validate the predictive 
value of a previously identified miRNA profile combined 
with clinicopathological factors in predicting clinical ben-
efit from first-line palliative systemic therapy in advanced 
mCRC.15 The same miRNA profile was quantified in serum 
specimens to test its predictive value as a liquid biomarker 
for clinical benefit to systemic treatment.
The predictive value of the tissue-derived six miRNA 
profile combined with the clinicopathological factors could 
not be validated in patients with mCRC starting with first-
line systemic therapy. Compared to the cohort previously 
used for identification of the putative predictive profile, the 
clinical parameters of the currently analyzed FF cohort dif-
fered significantly with the most important difference being 
that this cohort consisted of only patients with stage IV dis-
ease. Studies have shown that expression levels of specific 
miRNAs differ between clinical tumor stages.39,40 Although, 
for miR-17, miR-20a, miR-30a, and miR-92a previous stud-
ies have shown no significant relation between miRNA ex-
pression and stage.20,41,42 miR-92b expression has not been 
related to stage before and Zhu et al found lower levels of 
miR-98 expression in patients with stage III-IV disease com-
pared to patients with stage I-II disease.43 Since there was no 
significant difference in miRNA expression between patients 
with stage I-III (32%) vs stage IV (66.7%) disease in the 
previous cohort (see Table 1), we considered it worthwhile 
testing this signature in a cohort consisting of only patients 
with stage IV disease, who are starting first-line palliative 
systemic therapy.
Additionally, in the original study cohort, patients were 
treated with different chemotherapeutic agents, that is, 5-FU 
monotherapy, 5-FU with oxaliplatin-based regimens or 5-FU 
with irinotecan-based regimens, which was also an important 
covariate in the prediction model. In the current FF cohort, 
all patients received 5-FU with oxaliplatin-based chemother-
apy and therefore this covariate consisted of one factor.
Prior cohort FFPE FF cohort P value
Partial response (PR) 36 (44.4%) 37 (45.7%)
Stable disease (SD) 28 (34.6%) 39 (48.1%)
Progressive disease (PD) 15 (18.5%) 5 (6.17%)
Tissue specimen <.001
Primary tumor 70 (86.4%) 10 (13.5%)
Metastasis 11 (13.6%) 64 (86.5%)
Note: Data from the original FFPE cohort were adapted from Neerincx et al.15
Abbreviations: CEA, carcinoembryonic antigen; FF, fresh frozen; FFPE, Formalin-fixed paraffin-embedded; LDH, lactate dehydrogenase.
aAccording to RECIST 1.1. For the original FFPE cohort best response to first-line treatment was used as clinical endpoint, while for the FF cohort response after three 
to four cycles of chemotherapy was used as clinical endpoint in this table. 
T A B L E  1  (Continued)
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All six miRNAs were significantly higher expressed in 
the current FF cohort compared to the original FFPE co-
hort. Besides differences in patient characteristics, this could 
also be the result of methodological differences in RNA ex-
traction and quantification, due to updated kits available from 
Qiagen (after Exiqon merged with Qiagen, the assays from 
Exiqon were updated by Qiagen to exhibit improved perfor-
mance as stated in digital correspondence with Qiagen). In 
particular, the relatively low expressed miRNAs miR-17-5p, 
miR-30a-5p, miR-92b-3p, and miR-98-5p were significantly 
higher expressed in the updated assays.
Furthermore, the biopsy specimens in this cohort con-
sisted of FF tissue, mainly from metastatic lesions, whereas 
in the original FFPE cohort biopsies consisted of FFPE tissue 
samples, mainly from the primary tumor. Although studies 
have shown good correlations between miRNAs quantified 
in paired FF and FFPE samples independent of the employed 
methodology,5,44-47 this factor cannot be completely ruled out 
since an analysis of FF vs FFPE of paired samples using sim-
ilar methods has not been performed for this study.
We previously demonstrated that miRNA profiles of pri-
mary tumor and metastases are similar, making the biopsy 
FIGURE 4 Performance of the predictive models in the tissue cohort. A, ROC curve for clinical benefit (n = 76) vs progressive disease 
(n = 5) after three to four cycles of chemotherapy. Black line: the model with the clinicopathological factors: age, differentiation and prior use of 
chemotherapy. Red line: the final model after backward selection using the clinicopathological factors combined with miRNA expression levels of 
miR-17-5p, miR-92b-3p, and miR-98-5p. B, The predictive probabilities for CB vs PD calculated with the miRNA model presented with the red 
line in (A) (clinicopathological factors combined with miR-17-5p, miR-92b-3p, and miR-98-5p). The median predicted probability of PD and CB 
is both 0.16. C, ROC curve for objective response (CR and PR (n = 37)) vs SD and PD (n = 44) after three to four cycles of chemotherapy. D, The 
predictive probabilities for CR and PR vs SD and PD calculated with the miRNA model presented with the red line in (C) (differentiation, miR-92b-
3p). Median predicted probabilities are 0.47 and 0.58 for CR/PR and SD/PD, respectively. AUC, area under the curve; CB, clinical benefit; diff., 
differentiation; CR, complete response; PD, progressive disease; PR, partial response; ROC, receiver operator characteristics; SD, stable disease
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site an unlikely explanation for differences in miRNA expres-
sion levels.16 The miRNAs selected for this study were based 
on next generation sequencing (NGS) results from FF tissue 
of 88 patients with advanced CRC as described previously 
by Neerincx et al.15 The initial clinical endpoint in that study 
was clinical benefit vs progressive disease defined as best 
response to first-line treatment using Response Evaluation 
Criteria in Solid Tumors (RECIST version 1.1).29 In the study 
presented here, the response was assessed at first evaluation 
after three to four cycles of systemic therapy. In this cohort, 
only five patients had progressive disease at first evaluation 
(6.8%). Although this is a low number for predictive model-
ing, the miRNAs and clinicopathological parameters selected 
for this study are based on two independent cohorts of a total 
of 169 patients.15 The patient cohort in the current study was 
used for further validation of the miRNAs and clinicopath-
ological parameters. If these parameters were truly predic-
tive for response to chemotherapy a clinically relevant model 
should identify these five patients as nonresponders.
Using other evaluation time points (ie, after six to eight 
cycles, progression-free survival 6 or 9 months) did not im-
prove the predictive value either.
F I G U R E  5  Performance of the predictive models in the serum cohort. A, ROC curve analysis for prediction of CR/PR (n = 46) vs SD/
PD (n = 47) after three to four cycles of chemotherapy in the serum cohort. Black line: the model with the clinicopathological factors: age, 
differentiation and prior use of chemotherapy. Red line: the final model after backward selection using the clinicopathological factors combined 
with expression levels of miR-92a-3p and miR-98-5p. B, Individual predicted probabilities of the model with miRNAs presented with the red 
line in (A) for CR/PR vs SD/PD after three to four cycles of chemotherapy (prior chemo, differentiation, miR-92a-3p and miR-98-5p). Median 
predicted probability for CR/PR and SD/PD was 0.42 and 0.59, respectively. C, Correlation plot of log2 normalized tissue miRNA expression levels 
(x-axis) and log2 normalized serum miRNA expression levels (y-axis). Data are presented for miR-17-5p only, similar results were observed for 
other miRNAs (data not shown). AUC, area under the curve; CR, complete response; diff., differentiation; PD, progressive disease; PR, partial 
response; ROC, receiver operator characteristics; SD, stable disease.
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miRNA expression by tumor cells may affect serum lev-
els. This depends on the balance between the expression 
levels of tumor cells and the endogenous production of 
normal (circulating blood) cells in the body. High miRNA 
expression and release by tumor cells and low endogenous 
production are ideal for an optimal predictive biomarker. 
Here, three of six miRNAs also originate from blood cells 
(miR-17-5p, miR-92a-3p, and miR-20a-5p) and therefore 
have high baseline serum expression levels.32,48 This was 
confirmed in the current study. Consequently, miRNAs re-
leased from tumors may be insufficient to significantly alter 
these high baseline levels. On the contrary, miR-30a-5p, 
miR-92b-3p, and miR-98-5p were proven to have low base-
line serum expression levels, but are also expressed at low 
levels in CRC tissue. Again, these low miRNA levels re-
leased from tumors might be insufficient to allow detection 
(with current technology) of alterations in baseline serum 
expression levels.
F I G U R E  6  miRNA expression in the original FFPE cohort compared to the fresh frozen cohort. The original FFPE cohort was divided in 
stage I-III and IV. The cohort consisted only of patients with stage IV disease (IV_FF). Differences in expression were compared between stadium 
I-III (n = 26) and IV (n = 54) from the original FFPE cohort, and between stadium IV (n = 54) from the original FFPE cohort and IV_FF (n = 81) 
from the fresh frozen cohort using a two-tailed unpaired t test. Log2 expression levels are presented as average from duplicate measurements 
relative to miR-16-5p. miRNA data were adapted from Neerincx et al.15 NS: not significant. FF, fresh frozen; FFPE, formalin-fixed paraffin-
embedded; IV_FF, stadium IV fresh frozen cohort
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Nevertheless, previous studies have identified a pre-
dictive and/or prognostic value in CRC of serum expres-
sion levels of four (miR-17-5p, miR-20a-5p, miR-30a-5p, 
miR-92a-3p) of the six miRNAs selected for this study.49-
51 Probably other factors, for example the composition of 
the tumor microenvironment, the percentage of immune 
cell infiltration or circulating inflammatory indicators, 
which are also important factors for therapy response, may 
alter ci-miRNA levels as well. In our dataset the addition 
of miR-92a-3p and miR-98-5p significantly improved the 
AUC of the ROC curve for predicting response to chemo-
therapy. However, as demonstrated by the wide the range 
of calculated predicted probabilities in Figure 5B, the pre-
dictive value remains moderate and as such not useful in 
clinical practice.
To reduce background noise of endogenous miRNAs in 
blood cells, miRNAs could be quantified in exosomes. It is 
hypothesized that exosomes released from tumor cells are en-
riched with a tumor specific miRNA signature.52
The predictive models generated from our previous cohort 
could not be validated in the current dataset. In the adjusted 
models for the current FF cohort, serum miR-98-5p and miR-
92b-3p levels improved response prediction compared to the 
clinicopathological factors alone. The other four miRNAs 
that were found predictive by others49-51 were excluded from 
the models because of insignificance and could not be vali-
dated in this cohort.
A different miRNA panel or replacing some miRNAs 
of the current signature could possibly lead to a more pre-
dictive model. However, the present study investigated the 
clinical value of our previously identified prediction model. 
The identification of novel predictive miRNAs for the use as 
clinical biomarker is beyond the scope of the current study 
and requires further investigation.
In conclusion, despite the known role of miRNAs in can-
cer biology and their favorable characteristics to serve as 
biomarkers for clinical benefit from systemic treatment, the 
predictive miRNA signature which was previously identified 
did not show significant strength to predict treatment benefit 
in the present sizeable cohort of patients with mCRC undergo-
ing first-line combination chemotherapy. This could be partly 
due to differences in patient population and the materials and 
methods used. It emphasizes the importance of thorough re-
search on miRNAs as a predictive marker prior to using it in 
clinical decision-making. Potential improvements, by select-
ing miRNAs in circulating vesicles may provide additional 
value in this matter and requires additional evaluation.
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